Agile Therapeutics Strengthens Commercial Leadership Team
January 02 2020 - 8:00AM
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare
company, today announced the appointment of Kimberly Whelan as Vice
President of Market Access. Ms. Whelan has over 35 years of
experience in the healthcare industry working in finance, sales,
marketing, business development, and managed markets.
Ms. Whelan is responsible for overseeing the development and
execution of Agile’s market access strategy in preparation for the
potential commercialization of the company’s lead product
candidate, Twirla® (AG200-15), which has a PDUFA goal date of
February 16, 2020.
At the same time, Agile has filled two additional positions to
further strengthen its finance and marketing capabilities. Charles
S. Grass, CMA, has been named Senior Director, Finance and Matthew
Riley has been named Product Manager.
“We remain focused on seeking FDA approval of Twirla and
building a robust women’s health company. We continue to make
strategic investments and build our team to achieve those goals,”
said Al Altomari, Chairman and Chief Executive Officer of
Agile.
About Twirla® (AG200-15) Twirla
(levonorgestrel/ethinyl estradiol transdermal system) or AG200-15
is an investigational, once-weekly combined hormonal contraceptive
(CHC) patch that contains the active ingredients ethinyl estradiol
(EE), a type of estrogen, and levonorgestrel (LNG), a type of
progestin. Twirla is designed to be applied once weekly for three
weeks, followed by a week without a patch. The Company has
completed its Phase 3 clinical trials of Twirla and is pursuing
regulatory approval in the U.S. after resubmitting a New Drug
Application (NDA) for Twirla on May 16, 2019.
About Agile Therapeutics, Inc.
Agile Therapeutics is a forward-thinking women's healthcare
company dedicated to fulfilling the unmet health needs of today’s
women. Our product candidates are designed to provide women with
contraceptive options that offer freedom from taking a daily pill,
without committing to a longer-acting method. Our lead product
candidate, Twirla® (ethinyl estradiol and levonorgestrel
transdermal system), also known as AG200-15, is an investigational,
non-daily prescription contraceptive. Twirla is based on our
proprietary transdermal patch technology, called Skinfusion®, which
is designed to allow drug delivery through the skin. For more
information, please visit the company website at
www.agiletherapeutics.com. The Company may occasionally disseminate
material, nonpublic information on the Company’s website.
Contact: Investor Relations – 609-683-1880
Source: Agile Therapeutics, Inc.
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From Apr 2023 to Apr 2024